Andrea van Elsas
InvestorPartner at Third Rock Ventures
Oakland, California
Writes $100K – $5M checks · typically $100K
About
Andrea van Elsas joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He was previously CSO at Aduro Biotech, co-founded BioNovion, held immuno-oncology roles at Organon, and is a co-inventor on the original anti-CTLA-4 patents behind ipilimumab.
Invests in
BiotechHealthtechMedical Devices
Experience
- Third Rock VenturesPartnercurrent2022 — presentSan Francisco Bay Area
- Third Rock VenturesVenture Partner2020 — 2022San Francisco Bay Area
- Azalea TherapeuticsBoard Membercurrent2025 — presentBerkeley, California, United States
- Clasp TherapeuticsBoard Membercurrent2023 — presentBoston, Massachusetts, United States
- Clasp TherapeuticsChief Scientific Officer2021 — 2024Cambridge, Massachusetts, United States
- IREYA Consulting BVOwnercurrent2011 — presentOss, Netherlands
- Lava Therapeutics B.V.Scientific Advisory Board Chair2018 — 2025Netherlands
- Lava Therapeutics B.V.Board Member2018 — 2020Netherlands
- Mendus ABBoard Member2019 — 2024Leiden, South Holland Province, Netherlands
- InteRNA Technologies BVBoard Member2019 — 2023Utrecht City, Utrecht Province, Netherlands
- Abata TherapeuticsChief Scientific Officer2021 — 2023Cambridge, Massachusetts, United States
- Gilde HealthcareOperational Partner2017 — 2020Utrecht Area, Netherlands
- Aduro BiotechCSO2017 — 2020Oss, Netherlands & Berkeley, CA
- Aduro Biotech EuropeCSO & Director2015 — 2017Eindhoven Area, Netherlands
- BioNovionChief Scientific Officer2012 — 2017Oss, Netherlands
- AM-PharmaVP Research2011 — 2015Bunnik, Netherlands
- Merck Sharp & DohmeSenior Research Fellow2009 — 2011
- Schering-Plough Research InstituteDirector Tumor Immunology2007 — 2009
- OrganonDirector Tumor Immunology2007
- Organon PharmaceuticalsSection Head2004 — 2006
- Organon(Senior) Scientist to Fellow1999 — 2004
- KWF KankerbestrijdingResearch Fellow1997 — 1999
- UC Berkeleypostdoctoral fellow1997 — 1998
- Leiden University Medical Centergraduate student1990 — 1996
Education
- Leiden UniversityPhD, Immunology1990 — 1996
- University of AmsterdamMS, Molecular and Cell Biology1984 — 1990
- RSG West-FrieslandVWO diploma, Gymnasium B1978 — 1984
Skills & more
Immunology50Oncology22Biotechnology32Project Management5Clinical Development17Drug Discovery57Cancer21Pharmacology11Antibodies8Cell1Molecular Biology4Biopharmaceuticals1
+7 more
Cell BiologyLife SciencesRGenomicsPharmaceutical IndustryBiochemistryClinical ResearchLanguages Dutch · English · German · Greek
From Andrea's professional profile.
Investments
Board seats
Azalea TherapeuticsClasp TherapeuticsLava Therapeutics
Per the firm's website.
Colleagues at Third Rock Ventures
Abbie Celniker
Investor at Third Rock Ventures
Adam Tebbe
Investor at Third Rock Ventures
Alan Ezekowitz
Investor at Third Rock Ventures
Alison Connors
Investor at Third Rock Ventures
Amanda Chan
Investor at Third Rock Ventures
Andrew Warren
Senior Associate at Third Rock Ventures
Angelo Severino
Investor at Third Rock Ventures
Ava Brunelle
Investor at Third Rock Ventures
Network12
Abbie Celniker
Investor at Third Rock Ventures
Alan Ezekowitz
Investor at Third Rock Ventures
Andrew Warren
Senior Associate at Third Rock Ventures
Barbara Weber
Venture Partner at Third Rock Ventures
Beryl Cummings
Senior Associate at Third Rock Ventures
Cary Pfeffer
Investor at Third Rock Ventures
Charles Homcy
Investor at Third Rock Ventures
Christoph Lengauer
CSO at Curie.Bio
Craig Muir
Investor at Third Rock Ventures
David Kaufman
Investor at Third Rock Ventures
George C. Petrocheilos
Co-Founder and Managing Partner at Catalio Capital Management, LP
George Xu
Senior Associate at Third Rock Ventures
Investors connected to Andrea in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Andrea van Elsas?
- Andrea van Elsas joined Third Rock Ventures as a venture partner in 2020 and became partner in 2022. He was previously CSO at Aduro Biotech, co-founded BioNovion, held immuno-oncology roles at Organon, and is a co-inventor on the original anti-CTLA-4 patents behind ipilimumab.
- Where does Andrea van Elsas work?
- Andrea van Elsas is Partner at Third Rock Ventures.
- What does Andrea van Elsas invest in?
- Andrea van Elsas invests in Biotech, Healthtech, Medical Devices.
- What check size does Andrea van Elsas write?
- Andrea van Elsas typically writes checks of $100K – $5M.
- What boards does Andrea van Elsas sit on?
- Andrea van Elsas holds tracked board seats at Azalea Therapeutics, Clasp Therapeutics, Lava Therapeutics.
- Where did Andrea van Elsas go to school?
- Andrea van Elsas studied at Leiden University (PhD, Immunology); University of Amsterdam (MS, Molecular and Cell Biology); RSG West-Friesland (VWO diploma, Gymnasium B).
Same school
Also attended Leiden University76
Joost HollemanInvestor at Prime VenturesFredric PetitPartner, Head of Materials & Packaging at Emerald Technology Ventures AgJeroen PlinkVenture Partner at LegalTechThijs SchaapInvestment manager at NoaberRoel BulthuisInvestor at SynconaAina CabreroInvestor & Scientist at Planet A Ventures
+ 70 more
Also attended University of Amsterdam175
Job van der VoortCo-founder & CEO of RemoteTorjusInvestor at InvestinorDamien van der BijlInvestment Director at Capricorn Venture PartnersFreya WordsworthAssociate at Nauta CapitalEmil SchaeferInvestor at Index VenturesDjoni de VosPrincipal at Keen Venture Partners
+ 169 more
Shared employers
Also worked at Third Rock Ventures78
Lisa PurcellInvestor at Third Rock VenturesPaul MeloneInvestor at Third Rock VenturesKevin MunnellyInvestor at Third Rock VenturesAmanda ChanInvestor at Third Rock VenturesJigar RaythathaInvestor at Third Rock VenturesOlie LuchitskyInvestor at Third Rock Ventures
+ 72 more
Also worked at Clasp Therapeutics1
Also worked at Lava Therapeutics B.V.1
Also worked at Gilde Healthcare15
Anastasia BudinskayaInvestor at NFXPieter van der MeerManaging Partner at Gilde HealthcareArthur FrankenGeneral Partner at Gilde HealthcareGeoff PardoGeneral Partner at Gilde HealthcareJanke DittmerGeneral Partner at Gilde HealthcareJasper van GorpManaging Partner at Gilde Healthcare
+ 9 more